Zevra Therapeutics NASDAQ: ZVRA reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier, driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease type C, or NPC. Net U.S. product revenue from MIPLYFFA reached $34 million in the quarter, rising 12.6% sequentially and 52% from the prior-year period, according to Chief Financial Officer Justin Renz. The company also reported $3.6 million in net reimbursements from its global expanded-access program and $0.2 ...